New CAR-T cells targeting multiple B-cell markers to treat blood cancers
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies
This study is testing a new type of CAR-T cell therapy that targets three different markers on certain blood cancers, like acute lymphoblastic leukemia, to help improve treatment and reduce the chances of relapse, and patients may have the chance to try this exciting new therapy in a clinical trial.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10892297 on NIH RePORTER |
What this research studies
This research focuses on developing a novel type of CAR-T cell therapy that targets three different markers (CD19, CD20, and CD22) on B-cell malignancies, such as acute lymphoblastic leukemia. The approach aims to improve the effectiveness of existing CAR-T therapies by addressing the common issue of relapses due to antigen loss or CAR-T cell exhaustion. By using a unique costimulatory domain (OX-40), the researchers hope to enhance the persistence and activity of these CAR-T cells in the body. Patients may have the opportunity to receive these innovative CAR-T cells in a clinical trial setting.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with B-cell malignancies, such as acute lymphoblastic leukemia or non-Hodgkin's lymphoma, who have not responded to standard therapies.
Not a fit: Patients with B-cell malignancies who are in remission or those with other types of cancers may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with B-cell malignancies, potentially reducing relapse rates and improving long-term outcomes.
How similar studies have performed: Previous research has shown promising results with CAR-T therapies targeting single antigens, but this approach of targeting multiple antigens simultaneously is relatively novel and untested in humans.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Vasu, Sumithira — Ohio State University
- Study coordinator: Vasu, Sumithira
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.